A plethora of new antidiabetic medications, particularly glucagon-like peptide-1 receptor agonists (GLP-1RAs), have demonstrated positive cardiometabolic effects with improved glycemic control, weight loss, blood pressure control, and lower inflammation and thus have proven benefits in reducing rates of nonfatal acute myocardial infarction (AMI), stroke, and cardiovascular death.4 The gene discussed is GLP1R; the disease is myocardial infarction.